Moreover, it was previously reported that bromhexine, an FDA-approved ingredient in mucolytic cough suppressants, had the capacity to inhibit TMPRSS2 activity and to reduce prostate cancer enlargement and metastases [188]. Here, TMPRSS2 is linked to prostate cancer.